Agios Pharmaceuticals (AGIO - Get Report) was upgraded to outperform from perform at Oppenheimer. $75 price target. Analysts have higher expectations for the company's new potential hematology drugs, Oppenheimer said.
Outfront Media (OUT - Get Report) was downgraded to neutral from buy at Goldman Sachs. $27 price target. The valuation is less attractive, relative to Lamar Advertising at current levels, Goldman said.